Baird Maintains Outperform on Regenxbio, Raises Price Target to $32
REGENXBIO, Inc.
REGENXBIO, Inc. RGNX | 0.00 |
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:
RGNX) with a Outperform and raises the price target from $27 to $32.
Baird Maintains Outperform on Regenxbio, Raises Price Target to $32
REGENXBIO, Inc. RGNX | 0.00 |